MicroRNA 217 (miR-217)

MicroRNA 217 (miR-217) is a small, non-coding RNA molecule that regulates gene expression post-transcriptionally by binding target mRNAs, resulting in their degradation or translation inhibition[1][4]. miR-217 is differentially expressed in several cancer types and disease states. It has been shown to function both as a tumor suppressor and as an oncogenic regulator, depending on cellular context and disease stage[2][3]. miR-217 influences multiple cellular processes, including proliferation, apoptosis, migration, invasion, and senescence, by targeting several oncogenes and tumor suppressor genes such as KRAS, CAGE, SIRT1, and PTEN[3]. It can modulate drug responses by affecting cellular targets involved in chemotherapy sensitivity, including EGFR and HER2, and has a documented feedback loop with the cancer-testis antigen CAGE, influencing resistance to anticancer therapies[3]. miR-217 is being investigated as both a therapeutic target and a biomarker, especially in oncology[1][2][3].

Other names

hsa-mir-217MIRN217MIR217mir-217miR-217

Modulates response to anticancer drugs by regulating targets such as CAGE, EGFR, and HER2. Suppresses oncogenes or tumor suppressors at post-transcriptional level.